Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PHGDH | O43175 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2617853 | 1.00 | SIRT6 (0.41) | SIRT6MAPTHTTLMNAPHGDH | |
| SCHEMBL2118334 | 0.92 | ENPP2 (0.43) | SIRT6MAPTLMNAALDH1A1PIK3CD | |
| SCHEMBL2617826 | 0.92 | ENPP2 (0.43) | SIRT6MAPTLMNAALDH1A1PIK3CD | |
| SCHEMBL2120611 | 0.91 | SIRT6 (0.41) | SIRT6MAPTLMNAALDH1A1PIK3CD | |
| SCHEMBL2617857 | 0.91 | SIRT6 (0.41) | SIRT6MAPTLMNAALDH1A1PIK3CD | |
| SCHEMBL2617869 | 0.88 | SIRT6 (0.40) | SIRT6MAPTHTTLMNAPHGDH | |
| SCHEMBL2120935 | 0.88 | SIRT6 (0.40) | SIRT6MAPTHTTLMNAPHGDH | |
| SCHEMBL2617806 | 0.88 | SIRT6 (0.40) | SIRT6MAPTHTTLMNAPHGDH | |
| SCHEMBL2617861 | 0.85 | AR (0.41) | FFAR1PIK3CDPIK3CA | |
| SCHEMBL2118296 | 0.85 | AR (0.41) | FFAR1PIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507474-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2013-08-13 | — | — | US | disclosed |
| US-8507474-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2013-08-13 | — | — | US | disclosed |
| EP-2443091-B1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INT BV (NL) | 2013-04-03 | — | — | EP | disclosed |
| US-20120094981-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2012-04-19 | — | — | US | disclosed |
| US-20120094981-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094981-A1 | ANTHELMINTIC AGENTS AND THEIR USE | ABCB11, ACHE, CMA1 | SIRT6 1479/4885MAPT 2856/4885HTT 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.